21.06.2011 • NewsTevaTeva Pharmaceutical IndustriesMylan

Trial Set For Teva-Mylan Copaxone Lawsuit

A U.S. court on Friday denied a motion by Teva Pharmaceutical Industries for summary judgment in the Copaxone patent infringement lawsuit it has brought against Mylan Inc.    

Teva is suing generic drugmaker Mylan for infringement of patents covering Teva's top-selling Copaxone multiple sclerosis drug.      

Mylan said on Friday that the U.S. District Court for the Southern District of New York has denied Teva's motion for summary judgment.      

In addition, the court set a start date of July 11 for the trial regarding Mylan's inequitable conduct affirmative defense.      

The remaining issues will be tried beginning Sept. 7, Mylan said in a statement.      

The potential for a generic Copaxone is a major issue weighing on shares of Israel-based Teva.

 

 

 

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read